Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
ConditionAnti Phospholipid Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNew Valley University
About this trial
AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).
Eligibility criteria
Qualifiers
Adults aged ≥18 years
Patients with anemia consistant with hemolysis.
Patient diagnosed with antiphospholipid syndrome.
Informed consent obtained
Disqualifiers
Age less than 18 years.
Other causes of anemia than autoimmune hemolysis.
Trial design
Treatments tested in this trial
- Hemoglobin
- Coombs test
Treatment groups
230 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov